UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~December 31, 2017

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number: 0-12697

Dynatronics Corporation

(Exact name of registrant as specified in its charter)

Utah	87-0398434
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

7030 Park Centre Drive, Cottonwood Heights, UT 84121

(Address of principal executive offices, Zip Code)

(801) 568-7000

(~~Registrant's~~Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☑~~Yes~~ ☑Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of ~~"large~~“large accelerated filer,~~" "accelerated~~” “accelerated filer,~~" "smaller~~” “smaller reporting company,"” and ~~"emerging~~“emerging growth ~~company"~~company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐ (Do not check if a smaller reporting company)	Smaller reporting company ☑
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐Yes ☐ No ☑ No

The number of shares outstanding of the ~~registrant's~~registrant’s common stock, no par value, as of ~~May 15, 2017 is 3,683,090.~~February 2, 2018 was 7,934,262.

DYNATRONICS CORPORATION

FORM 10-Q

QUARTER ENDED ~~MARCH~~December 31, 2017

TABLE OF CONTENTS

	Page Number

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements	1

Condensed Consolidated Balance Sheets (Unaudited) ~~As of March 31, 2017 and June 30, 2016~~	1

Condensed Consolidated Statement of Operations (Unaudited)	2

~~Condensed Consolidated Statements of Operations (Unaudited) Three and Nine months Ended March 31, 2017 and 2016~~	2

Condensed Consolidated Statements of Cash Flows (Unaudited) ~~Nine months Ended March 31, 2017 and 2016~~	3

Notes to Condensed Consolidated Financial Statements (Unaudited)	4

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	911

Item 3. Quantitative and Qualitative Disclosures ~~about~~About Market Risk	1617

Item 4. Controls and Procedures	1617

PART II. OTHER INFORMATION

Item 6. Exhibits	1718

Signatures	19

DYNATRONICS CORPORATION

Condensed Consolidated Balance Sheets
(Unaudited)

Assets
March 31,
2017

June 30,
2016

     Current assets:
Cash and cash equivalents $ 3,352,694 $ 966,183
Trade accounts receivable, less allowance for doubtful accounts of $459,700 as of March 31, 2017 and $389,050 as of June 30, 2016 2,925,080 3,523,731
Other receivables 29,793 10,946
Inventories, net 5,783,327 4,997,254
Prepaid expenses 221,013 256,735
Prepaid income taxes 1,072 -

          Total current assets 12,312,979 9,754,849

Property and equipment, net 4,578,087 4,777,565
Intangible assets, net 137,113 160,123
Other assets 693,408 580,161

          Total assets $ 17,721,587 $ 15,272,698

Liabilities and Stockholders' Equity

     Current liabilities:
Current portion of long-term debt $ 150,894 $ 137,283
Current portion of capital lease 191,134 183,302
Current portion of deferred gain 150,448 150,448
Line of credit 2,540,073 -
Warranty reserve 153,042 152,605
Accounts payable 2,489,795 1,914,342
Accrued expenses 322,373 358,787
Accrued payroll and benefits expense 537,056 1,034,688
Income tax payable - 2,895

          Total current liabilities 6,534,815 3,934,350

Long-term debt, net of current portion 497,019 553,191
Capital lease, net of current portion 3,137,202 3,281,547
Deferred gain, net of current portion 1,717,613 1,830,449
Deferred rent 113,501 85,151

          Total liabilities 12,000,150 9,684,688
Commitments and contingencies

     Stockholders' equity:
Preferred stock, no par value: Authorized 50,000,000 shares; 2,000,000 shares and 1,610,000 shares issued and outstanding as of March 31, 2017 and June 30, 2016, respectively 4,636,706 3,708,152
Common stock, no par value: Authorized 100,000,000 shares; 3,047,345 shares and 2,805,280 shares issued and outstanding as of March 31, 2017 and June 30, 2016, respectively 8,174,434 7,545,880
Accumulated deficit (7,089,703 ) (5,666,022 )

          Total stockholders' equity 5,721,437 5,588,010

          Total liabilities and stockholders' equity $ 17,721,587 $ 15,272,698

~~See accompanying notes to condensed consolidated financial statements.~~

DYNATRONICS CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)

Three Months Ended Nine Months Ended
March 31, March 31,
2017 2016 2017 2016

Net sales $ 7,715,955 $ 7,408,990 $ 24,592,043 $ 22,281,107
Cost of sales 5,014,175 4,922,570 16,022,269 14,606,877

Gross profit 2,701,780 2,486,420 8,569,774 7,674,230

Selling, general, and administrative expenses 3,153,257 2,620,238 8,768,851 7,445,023
Research and development expenses 230,594 249,995 818,954 769,223

Operating loss (682,071 ) (383,813 ) (1,018,031 ) (540,016 )

Other income (expense):
   Interest income 124 175 488 2,658
   Interest expense (74,992 ) (71,690 ) (198,084 ) (229,207 )
   Other income, net 2,208 4,640 79,943 9,635

Net other expense (72,660 ) (66,875 ) (117,653 ) (216,914 )

Loss before income taxes (754,731 ) (450,688 ) (1,135,684 ) (756,930 )

Income tax (provision) benefit - - - -

Net loss (754,731 ) (450,688 ) (1,135,684 ) (756,930 )

Deemed dividend on 8% convertible preferred stock - - (375,858 ) -
8% Convertible preferred stock dividend (93,979 ) (80,500 ) (271,756 ) (241,500 )
Net loss attributable to common stockholders $ (848,710 ) $ (531,188 ) $ (1,783,298 ) $ (998,430 )

Basic and diluted net loss per common share $ (0.28 ) $ (0.19 ) $ (0.61 ) $ (0.37 )

Weighted-average common shares outstanding:

Basic 3,022,443 2,731,282 2,914,229 2,681,493
Diluted 3,022,443 2,731,282 2,914,229 2,681,493

DYNATRONICS CORPORATION
Condensed Consolidated Balance Sheets
(Unaudited)

Assets	December 31, 2017	June 30, 2017

Current assets:
Cash and cash equivalents	$3,652,342	$254,705
Trade accounts receivable, less allowance for doubtful accounts of $383,356 as of December 31, 2017 and $382,333 as of June 30, 2017	7,385,608	5,281,348
Other receivables	139,366	33,388
Inventories, net	11,605,299	7,397,682
Prepaid expenses	893,933	503,800

Total current assets	23,676,548	13,470,923

Property and equipment, net	5,970,836	4,973,477
Intangible assets, net	7,516,028	2,754,118
Goodwill	7,872,863	4,302,486
Other assets	532,611	562,873

Total assets	$45,568,886	$26,063,877

Liabilities and Stockholders' Equity

Current liabilities:
Accounts payable	$4,451,050	$2,334,563
Accrued payroll and benefits expense	1,358,754	1,472,773
Accrued expenses	878,300	656,839
Income tax payable	9,654	8,438
Warranty reserve	205,850	202,000
Line of credit	6,742,979	2,171,935
Current portion of long-term debt	158,954	151,808
Current portion of capital lease	199,300	193,818
Current portion of deferred gain	150,448	150,448
Current portion of acquisition holdback	430,624	294,744

Total current liabilities	14,585,913	7,637,366

Long-term debt, net of current portion	386,632	461,806
Capital lease, net of current portion	2,986,689	3,087,729
Deferred gain, net of current portion	1,604,777	1,680,001
Acquisition holdback and earn out liability, net of current portion	2,716,667	750,000
Deferred rent	138,513	122,585

Total liabilities	22,419,191	13,739,487
Commitments and contingencies

Stockholders' equity:
Preferred stock, no par value: Authorized 50,000,000 shares; 4,889,000 shares and 3,559,000 shares issued and outstanding as of December 31, 2017 and June 30, 2017, respectively	11,641,816	8,501,295
Common stock, no par value: Authorized 100,000,000 shares; 7,864,715 shares and 4,653,165 shares issued and outstanding as of December 31, 2017 and June 30, 2017, respectively	19,802,351	11,838,022
Accumulated deficit	(8,294,472)	(8,014,927)

Total stockholders' equity	23,149,695	12,324,390

Total liabilities and stockholders' equity	$45,568,886	$26,063,877

See accompanying notes to condensed consolidated financial statements.

~~See accompanying notes to condensed consolidated financial statements.~~

DYNATRONICS CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
March 31,
2017 2016
Cash flows from operating activities:
       Net loss $ (1,135,684 ) $ (756,930 )
       Adjustments to reconcile net loss to net cash used in operating activities:
             Depreciation and amortization of property and equipment 161,961 168,439
             Amortization of intangible assets 23,010 25,912
             Amortization of other assets 92,323 38,529
             Amortization of building lease 188,950 188,950
             Gain on sale of property and equipment (19,252 ) -
             Stock-based compensation expense 171,798 81,075
             Change in provision for doubtful accounts receivable 70,650 (50,558 )
             Change in provision for inventory obsolescence 7,028 18,422
             Deferred gain on sale/leaseback (112,836 ) (112,836 )
             Change in operating assets and liabilities:
                  Receivables, net 509,154 58,447
                  Inventories, net (793,101 ) 35,108
                  Prepaid expenses 35,722 47,192
                  Other assets (205,570 ) 22,880
                  Income tax payable (3,967 ) 269,826
                  Accounts payable and accrued expenses 255,194 (706,208 )

                              Net cash used in operating activities (754,620 ) (671,752 )

Cash flows from investing activities:
       Purchase of property and equipment (164,181 ) (44,152 )
       Proceeds from sale of property and equipment 32,000 -

                              Net cash used in investing activities (132,181 ) (44,152 )

Cash flows from financing activities:
       Principal payments on long-term debt (42,561 ) (92,631 )
       Principal payments on long-term capital lease (136,513 ) (129,107 )
       Net change in line of credit 2,540,073 (1,909,919 )
       Proceeds from issuance of preferred stock, net 928,554 -
       Preferred stock dividends paid in cash (16,241 ) -

                              Net cash provided by (used in) financing activities 3,273,312 (2,131,657 )

                              Net change in cash and cash equivalents 2,386,511 (2,847,561 )

Cash and cash equivalents at beginning of the period 966,183 3,925,967

Cash and cash equivalents at end of the period $ 3,352,694 $ 1,078,406

Supplemental disclosure of cash flow information:
       Cash paid for interest $ 198,572 $ 247,545
Supplemental disclosure of non-cash investing and financing activity:
       Deemed dividend on 8% convertible preferred stock $ 375,858 $ -
       8% Preferred stock dividend paid in common stock $ 276,693 $ 241,500
       Accrued severance paid in common stock $ 185,000 $ -

DYNATRONICS CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)

	Three Months Ended		Six Months Ended
	December 31		December 31,
	2017	2016	2017	2016

Net sales	$18,081,333	$8,713,355	$30,879,304	$16,876,089
Cost of sales	12,311,354	5,640,048	20,769,933	11,008,094
Gross profit	5,769,979	3,073,307	10,109,371	5,867,995

Selling, general, and administrative expenses	5,109,809	2,851,236	8,932,511	5,615,594
Research and development expenses	553,487	309,476	805,336	588,360
Operating profit (loss)	106,683	(87,405)	371,524	(335,959)


Other income (expense):
Interest expense, net	(103,706)	(63,408)	(180,514)	(122,728)
Other income, net	11,371	55,494	21,985	77,735
Net other expense	(92,335)	(7,914)	(158,529)	(44,993)

Income (loss) before income taxes	14,348	(95,319)	212,995	(380,952)

Income tax (provision) benefit	-	-	-	-

Net income (loss)	14,348	(95,319)	212,995	(380,952)

Deemed dividend on convertible preferred stock and accretion of discount	(1,023,786)	(375,858)	(1,023,786)	(375,858)
Preferred stock dividend, cash	(104,884)	-	(104,884)	-
Convertible preferred stock dividend, in common stock	(200,594)	(88,792)	(387,655)	(177,777)

Net loss attributable to common stockholders	$(1,314,916)	$(559,969)	$(1,303,330)	$(934,587)

Basic and diluted net loss per common share	$(0.23)	$(0.19)	$(0.25)	$(0.33)

Weighted-average common shares outstanding:

Basic and diluted	5,735,159	2,881,111	5,241,604	2,861,299

See accompanying notes to condensed consolidated financial statements.

~~See accompanying notes to condensed consolidated financial statements.~~

DYNATRONICS CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
	Six Months Ended
	December 31
	2017	2016
Cash flows from operating activities:
Net income (loss)	$212,995	$(380,952)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property and equipment	184,010	106,098
Amortization of intangible assets	254,090	15,340
Amortization of other assets	40,681	60,069
Amortization of building capital lease	125,967	125,967
Gain on sale of property and equipment	(5,197)	(19,252)
Stock-based compensation expense	117,073	102,989
Change in allowance for doubtful accounts receivable	(6,978)	48,073
Change in allowance for inventory obsolescence	49,739	42,751
Deferred gain on sale/leaseback	(75,224)	(75,224)
Change in operating assets and liabilities:
Receivables, net	33,546	62,135
Inventories, net	(120,175)	(630,132)
Prepaid expenses	(297,144)	(174,016)
Other assets	(10,419)	(18,799)
Income tax payable	(1,236)	1,066
Accounts payable and accrued expenses	1,175,114	684,319

Net cash provided by (used in) operating activities	1,676,842	(49,568)

Cash flows from investing activities:
Purchase of property and equipment	(84,494)	(36,818)
Net cash paid in acquisition, net of cash received - see Note 2	(9,063,017)	-
Proceeds from sale of property and equipment	10,355	32,000

Net cash provided by (used in) investing activities	(9,137,156)	(4,818)

Cash flows from financing activities:
Principal payments on long-term debt	(68,028)	(84,239)
Principal payments on long-term capital lease	(95,558)	(90,373)
Payment of acquisition holdbacks	(44,744)	-
Net change in line of credit	4,571,044	-
Proceeds from issuance of preferred stock, net	6,600,121	928,554
Preferred stock dividends paid in cash	(104,884)	-

Net cash provided by (used in) financing activities	10,857,951	753,942

Net change in cash and cash equivalents	3,397,637	699,556

Cash and cash equivalents at beginning of the period	254,705	966,183

Cash and cash equivalents at end of the period	$3,652,342	$1,665,739

Supplemental disclosure of cash flow information:
Cash paid for interest	$172,893	$124,797
Supplemental disclosure of non-cash investing and financing activity:
Deemed dividend on convertible preferred stock and accretion of discount	$1,023,786	$375,858
Preferred stock dividends paid or to be paid in common stock	387,655	187,901
Preferred stock issued to acquire "Bird & Cronin"	4,000,000	-
Acquisition holdback	2,147,291	-
Conversion of preferred stock to common stock	7,459,600	-
Accrued compensation paid in common stock	-	26,388

See accompanying notes to condensed consolidated financial statements.

DYNATRONICS CORPORATION

~~NOTES~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

~~March~~December 31, 2017

NOTE 1. PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The condensed consolidated balance sheets as of ~~March~~December 31, 2017 and June 30, ~~2016,~~2017, the condensed consolidated statements of operations for the three and ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, and condensed consolidated statements of cash flows for the ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, were prepared by Dynatronics Corporation ~~(the "Company"~~and its subsidiaries (collectively, the “Company”) without audit pursuant to the instructions to Form 10-Q and the rules and regulations of the Securities and Exchange Commission ~~("SEC"~~(“SEC”). Certain information and disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles ("(“U.S. ~~GAAP"~~GAAP”) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all necessary adjustments, which consist only of normal recurring adjustments, to the financial statements have been made to present fairly the ~~Company's~~Company’s financial position, results of operations and cash flows. The results of operations for the three and ~~nine~~six months ended ~~March~~December 31, 2017, are not necessarily indicative of the results of operations that may be expected for the fiscal year ending June 30, ~~2017.~~2018. The Company previously filed with the SEC an ~~annual report~~Annual Report on Form 10-K ~~as amended,~~(the “2017 Form 10-K”) which included audited financial statements for each of the ~~two~~ years ended June 30, ~~2016~~2017 and ~~2015.~~2016. It is suggested that the financial statements contained in this Form 10-Q be read in conjunction with the financial statements and notes thereto contained in the ~~Company's most recent~~2017 Form ~~10-K, as amended.~~10-K.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Some of the more significant estimates relate to inventory, allowance for doubtful accounts, stock-based compensation and valuation allowance for deferred income taxes.

Significant Accounting Policies

There have been no changes to the ~~Company's~~Company’s significant accounting policies as described in the ~~Company's Annual Report on~~2017 Form ~~10-K for the fiscal year ended June 30, 2016.~~10-K.

NOTE 2. ACQUISITIONS

On October 2, 2017, the Company acquired substantially all of the assets of Bird & Cronin, Inc. (“B&C”), a manufacturer and distributor of orthopedic soft goods and specialty patient care products. The transaction is referred to as the “Acquisition”. The Acquisition will expand the Company’s sales in the orthopedic and patient care markets by leveraging the products and distribution network offered by B&C.

At the Closing of the Acquisition, the Company paid B&C cash of $9,063,017 and delivered 1,397,375 shares of its Series D Non Voting Convertible Preferred Stock (“Series D Preferred”) to B&C valued at approximately $3,533,333. The purchase price is subject to customary representations, warranties, indemnities, working capital adjustment and an earn-out payment ranging from $500,000 to $1,500,000, based on future sales. The balance of the earn-out liability at December 31, 2017 is $1,500,000. A holdback of cash totaling $647,291 and 184,560 shares of Series D Preferred valued at approximately $466,667 has been retained for purposes of satisfying adjustments to the purchase price.

In connection with the Acquisition, the Company completed a private placement of Series C Non Voting Convertible Preferred Stock (“Series C Preferred”) and common stock warrants to raise cash proceeds of $7,000,000 pursuant to the terms and conditions of a Securities Purchase Agreement entered into September 26, 2017 (the “Private Placement”). See Note 4 for details of the Private Placement.

Also in connection with the Acquisition, the Company entered into a lease with Trapp Road Limited Liability Company, a Minnesota limited liability company controlled by the former owners of B&C, to occupy the facility housing the B&C operations for a term of three years at annual rental payments of $600,000, payable in monthly installments of $50,000. The lease term will automatically be extended for two additional periods of two years each, without any increase in the lease payment, subject to the Company’s right to terminate the lease or to provide notice not to extend the lease prior to the end of the term. The Company also offered employees of B&C employment with Dynatronics at Closing including the Co-Presidents of B&C, Mike Cronin and Jason Anderson, who entered into employment agreements to serve as Co-Presidents of Bird & Cronin, LLC, the Company’s wholly-owned subsidiary that conducts the operations acquired in the Acquisition.

The Acquisition has been accounted for under the purchase method as prescribed by applicable accounting standards. Under this method, the Company has allocated the purchase price to the assets acquired and liabilities assumed at estimated fair values. The total consideration transferred or to be transferred, totaled $15,213,959. The following table summarizes the preliminary estimated fair value of the assets acquired and liabilities assumed as of the date of acquisition:

Cash and cash equivalents	$4,104
Trade accounts receivable	2,232,703
Inventories	4,137,181
Prepaid expenses	92,990
Property and equipment	1,228,000
Intangible assets	5,016,000
Goodwill	3,570,376
Warranty reserve	(5,000)
Accounts payable	(607,084)
Accrued expenses	(265,732)
Accrued payroll and benefits	(189,579)
Purchase price	$15,213,959

The estimates of fair value of identifiable assets acquired and liabilities assumed are preliminary, pending finalization of a valuation, and are subject to revisions that may result in adjustments to the values presented above.

Intangible assets subject to amortization relate to customer relationships of $4,313,000 with a useful life of ten years and other intangible assets of $83,000 with a useful life of five years. Intangible assets not subject to amortization relate to trade names of $620,000. The goodwill recognized from the Acquisition is estimated to be attributable, but not limited to, the acquired workforce and expected synergies that do not qualify for separate recognition. The full amount of goodwill and intangible assets are expected to be deductible for tax purposes.

As of December 31, 2017, the Acquisition earn out liability and holdbacks of $2,147,291 come due, contingent upon the terms set forth in the purchase agreement, as follows:

October 2, 2018	$180,624
April 1, 2019	466,667
August 15, 2019	1,500,000
Acquisition holdback	$2,147,291

The amounts of B&C’s net sales and net income included in the Company's consolidated statement of operations for the period from October 2, 2017 to December 31, 2017, were $5,701,507 and $455,052 respectively. Pro forma net sales and net loss of the combined operations had the acquisition date been July 1, 2016 are:

	Net Sales	Net Income (loss)
Unaudited supplemental pro forma July 1, 2017 to December 31, 2017	$37,337,488	$259,644
Unaudited supplemental pro forma July 1, 2016 to June 30, 2017	$60,027,677	$(285,951)

2017 supplemental pro forma earnings were adjusted to exclude $70,000 of acquisition-related costs incurred in 2017.

NOTE 3. NET ~~LOSS~~INCOME (LOSS) PER COMMON SHARE

Net ~~loss~~income (loss) per common share is computed based on the weighted-average number of common shares outstanding and, when appropriate, dilutive potential common stock outstanding during the period. Stock options, convertible preferred stock and warrants are considered to be potential common stock. The computation of diluted net ~~loss~~income (loss) per common share does not assume exercise or conversion of securities that would have an anti-dilutive effect.

Basic net ~~loss~~income (loss) per common share is the amount of net ~~loss~~income (loss) for the period available to each weighted-average share of common stock outstanding during the reporting period. Diluted net ~~loss~~income (loss) per common share is the amount of net ~~loss~~income (loss) for the period available to each weighted-average share of common stock outstanding during the reporting period and to each share of potential common stock outstanding during the period, unless inclusion of potential common stock would have an anti-dilutive effect.

~~The reconciliations between the basic and diluted weighted-average number of common shares outstanding for the three and nine months ended March 31, 2017 and 2016, are as follows:~~

Three Months Ended Nine Months Ended
March 31, March 31,
2017 2016 2017 2016
Basic weighted-average number of common shares outstanding during the period 3,022,443 2,731,282 2,914,229 2,681,493
Weighted-average number of dilutive potential common stock outstanding during the period - - - -
Diluted weighted-average number of common and potential common shares outstanding during the period 3,022,443 2,731,282 2,914,229 2,681,493

Outstanding options, warrants and convertible preferred stock for common shares not included in the computation of diluted net loss per common share because they were anti-dilutive, ~~totaled 5,165,008 and 4,167,814~~ for the three months ended ~~March~~December 31, 2017, and 2016, totaled 13,838,859 and 5,148,398, respectively, and ~~5,165,798 and 4,167,814~~ for the ~~nine~~six months ended ~~March~~December 31, 2017, and 2016, ~~respectively.~~

~~NOTE 3. STOCK-BASED COMPENSATION~~

~~Stock-based compensation cost is measured at the grant date, based on the estimated fair value of the award,~~totaled 12,114,132 and is recognized over the employee's requisite service period. The Company recognized $68,809 and $51,453 in stock-based compensation expense during the three months ended March 31, 2017 and 2016, respectively, and recognized $171,798 and $81,075 in stock-based compensation expense during the nine months ended March 31, 2017 and 2016,5,148,398, respectively. ~~These expenses were recorded as selling, general and administrative expenses in the condensed consolidated statements of operations.~~

~~Stock Options.~~ The Company maintained a 2005 equity incentive plan ("2005 Plan") for the benefit of employees. On June 29, 2015, the shareholders approved a new 2015 equity incentive plan ("2015 Plan") setting aside 500,000 shares of common stock for awards to eligible participants. No additional shares or awards will be granted under the 2005 Plan. The 2015 Plan was filed with the SEC on September 3, 2015. Incentive and nonqualified stock options, restricted common stock, stock appreciation rights, and other stock-based awards may be granted under the 2015 Plan. Awards granted under the 2015 Plan may be performance-based. As of March 31, 2017, there were 307,221 shares of common stock authorized and reserved for issuance available for future grants under the terms of the 2015 Plan.

~~The following table summarizes the Company's stock option activity under the 2005 and 2015 Plans during the nine-month period ended March 31, 2017:~~

Number of
Options

Weighted-
Average
Exercise
Price

Outstanding at beginning of period 121,557 $ 3.57
Granted 49,500 2.83
Exercised - -
Cancelled (2,639 ) 4.63
Outstanding at end of period 168,418 3.33

Exercisable at end of period 75,901 $ 4.47

~~The Black-Scholes option-pricing model is used to estimate the fair value of options granted under the Company's stock option plans.~~

Expected option lives and volatilities are based on historical data of the Company. The risk-free interest rate is based on the U.S. Treasury Bills rate on the grant date for constant maturities that correspond with the option life. Historically, the Company has not declared dividends on common stock and there are no plans to do so.

As of March 31, 2017, there was $267,641 of unrecognized stock-based compensation cost related to grants under the 2005 and 2015 Plans that is expected to be expensed over a weighted-average period of 4.97 years. There was $1,817 of intrinsic value for options outstanding as of March 31, 2017.

NOTE 4. CONVERTIBLE PREFERRED STOCK AND COMMON STOCK WARRANTS

During quarter ended December ~~16, 2016~~31, 2017, the ~~shareholders approved an increase to the aggregate number of~~Company issued 25,000 shares of ~~preferred~~common stock ~~that~~upon conversion of 25,000 shares of Series B Convertible Preferred Stock (the “Series B Preferred”). As of December 31, 2017, the Company ~~is authorized to issue from 5,000,000~~had a total of 3,459,000 shares ~~to 50,000,000 shares.~~

~~On December 28, 2016, the Company completed a private placement with affiliates~~ of Prettybrook Partners, LLC ("Prettybrook") and certain other purchasers (collectively with Prettybrook, the "Preferred Investors") for the offer and sale of the remaining designated 390,000 shares of the Company's Series A 8% Convertible Preferred Stock (the ~~"Series A Preferred") for gross proceeds of approximately $975,000. Proceeds from the private placement were recorded net of offering costs incurred. The~~ “Series A Preferred ~~is convertible to common stock~~”) and Series B Preferred outstanding. Dividends payable on ~~a 1:1 basis. A forced conversion can be initiated based on a formula related to share price~~these shares accrue at the rate of 8% per year and trading volumes as outlined in the Certificate Designating the Preferences, Rights and Limitations of the Series A Preferred ("Series A Designation"). The dividend is fixed at 8% and is payable in either cash or common stock subject to conditions contained in the Series A Designation. This dividend isare payable quarterly ~~and equates to an annual payment of $400,000~~ in ~~cash~~stock or ~~a value~~cash. The Company generally pays the dividends in common stock. The formula for paying this dividend in common stock ~~based~~can change the effective yield on the ~~trading~~dividend to more or less than 8% depending on the price of the stock at the time of issuance.

In connection with the Acquisition of B&C on the date the dividend is declared. Certain redemption rights are attached to the Series A Preferred, but none of the redemption rights for cash are deemed outside the control of the Company. The redemption rights deemed outside the control ofOctober 2, 2017, the Company ~~require~~issued 2,800,000 shares of Series C Preferred with common stock ~~payments or an increase in the dividend rate.~~warrants (“Series C Warrants”) and 1,581,935 shares of its Series D Preferred. The Series ~~A Preferred includes a liquidation preference under which Preferred Investors would receive cash equal to the stated value~~C Warrants have an exercise price of their stock plus unpaid dividends. In accordance with the terms of the sale of the Series A Preferred, the Company was required to register the underlying common shares associated with the Series A Preferred and the Series A Warrants issued to the Preferred Investors in the private placement, as described below. That registration statement was filed on Form S-3 on January 28, 2017 and amended on February 1, 2017. The registration statement became effective on February 10, 2017.

~~The Series A Preferred votes on an as-converted basis, one vote for each~~$2.75 per share of common stock ~~issuable~~and a term of six years. They may not be exercised unless and until shareholder approval has been obtained. Each share of Series C Preferred and Series D Preferred was convertible into one share of common stock of the Company automatically upon, but not before receipt of shareholder approval required under applicable Nasdaq Marketplace Rules. A holder of Series C Preferred was able elect to retain the Series C Preferred and not convert, subject to future beneficial ownership limitations and loss of preferential rights. At the Company’s 2017 Annual Meeting of Shareholders, held on November 29, 2017, the Company sought and obtained shareholder approval as described above. On November 29, 2017, the Company issued 1,360,000 shares of Common Stock in conversion of a portion of the Series AC Preferred ~~provided, however, that no holder of Series A Preferred shall be entitled to cast votes for the number of~~and 1,581,935 shares of ~~common stock issuable upon~~Common Stock in conversion of such Series A Preferred held by such holder that exceeds the quotient of (x) the aggregate purchase price paid by such holder of Series A Preferred for its Series A Preferred, divided by (y) the greater of (i) $2.50 and (ii) the market price of the common stock on the trading day immediately prior to the date of issuance of such holder's Series A Preferred. The market price of the common stock on the trading day immediately prior to the date of issuanceall of the Series ~~A Preferred in~~D Preferred. As of December ~~2016 was $2.37 per share. Based on a $975,000 investment~~ ~~at $2.50 per share and a $2.37 per share market price,~~31, 2017, the ~~number of shares of potential common stock eligible for voting by the Preferred Investors is 390,000.~~

~~The Preferred Investors purchased a total of 390,000~~Company had 1,440,000 shares of Series AC Preferred and received in connection with such purchase common stock purchase warrants (collectively, the "Series A Warrants"); (i) A-Warrants, exercisable by cash exercise only, to purchase 292,500 shares of common stock, and (ii) B-Warrants, exercisable by "cashless exercise", to purchase 292,500 shares of common stock, but only after exercise of holder's A-Warrants.outstanding. The Series ~~A Warrants~~C Preferred shares are ~~exercisable for 72 months from the date of issuance~~non-voting, do not receive dividends, and ~~carry a put feature in the event of a change in control. The put right is not subject to derivative accounting as all equity holders are treated the same in the event of a change in control.~~have no liquidation preferences or redemption rights.

The ~~Company's shareholders originally authorized~~Company determined that the ~~issuance~~Series C Preferred contain a beneficial conversion feature resulting in a deemed dividend of ~~2,000,000 shares~~$829,559. Upon conversion of a portion of the Series AC Preferred in June, 2015. The Company sold and issued 1,610,000 shares of Series A Preferred in June 2015, leaving 390,000 shares available for future issuance. Those remaining 390,000 shares were sold and issued in December 2016 as described in this Note 4. The only difference betweenduring the shares of Series A Preferred issued in June 2015 and those issued in December 2016 is that the formula determining voting rights for the shares issued in June 2015 indicated a cutback in the voting power of those shares ~~as required by the Series A Designation.~~ The shares of Series A Preferred issued in December 2016 were not subject to any cutback. For information regarding the original issuance of the Series A Preferred in June 2015, see the Company's Annual Report on Form ~~10-K~~ ~~for~~ ~~the~~ ~~fiscal year ended June 30, 2016.~~

The Series A Preferred includes a conversion right at a price that creates an embedded beneficial conversion feature. A beneficial conversion feature arises when the conversion price of a convertible instrument is below the per share fair value of the underlying stock into which it is convertible. The conversion price is 'in the money' and the holder realizes a benefit to the extent of the price difference. The issuer of the convertible instrument realizes a cost based on the theory that the intrinsic value of the price difference (i.e., the price difference times the number of shares received upon conversion) represents an additional financing cost. The conversion rights associated with the Series A Preferred issued by the Company do not have a stated life and, therefore, the total beneficial conversion feature amount of $375,858 associated with the shares issued in December 2016 was recorded as a deemed dividend on the date the shares were issued. The $375,858 dividend is added to the net loss to arrive at the net loss applicable to common stockholders for purposes of calculating loss per share for the ninethree months ended ~~March~~December 31, ~~2017.~~

2017, accretion of $194,227 in discounts was recognized.

NOTE 5. ~~COMMON STOCK~~COMPREHENSIVE INCOME (LOSS)

~~On December 16, 2016, the shareholders approved an increase to the aggregate number of shares of common stock that the Company is authorized to issue from 50,000,000 shares to 100,000,000 shares.~~

~~NOTE 6. COMPREHENSIVE LOSS~~

For the three and ~~nine~~six months ended ~~March~~December 31, 2017 and 2016, comprehensive ~~loss~~income (loss) was equal to the net ~~loss~~income (loss) as presented in the accompanying condensed consolidated statements of operations.

NOTE 7.6. INVENTORIES

Inventories consisted of the following:

	December 31, 2017	June 30, 2017
Raw materials	$6,332,413	$3,766,940
Work in process	421,861	470,721
Finished goods	5,303,501	3,562,758
Inventory obsolescence reserve	(452,476)	(402,737)
	$11,605,299	$7,397,682

March 31,
2017

June 30,
2016

Raw materials $ 2,274,898 $ 2,059,048
Finished goods 3,931,215 $ 3,353,964
Inventory obsolescence reserve (422,786 ) (415,758 )
$ 5,783,327 4,997,254

NOTE 8.7. RELATED-PARTY TRANSACTIONS

The Company ~~currently~~ leases office, manufacturing and warehouse ~~space~~facilities in Detroit, Michigan, ~~and~~ Hopkins, Minnesota, Northvale, New Jersey and Eagan, Minnesota from ~~two~~employees, shareholders and ~~former independent distributors on an annual basis under operating lease arrangements. Management believes~~entities controlled by shareholders, who were previously principals of businesses acquired by the ~~lease agreements are on an arms-length basis and the terms are equal to or more favorable than would be available to the Company from third parties.~~Company. The ~~expense~~combined expenses associated with these related-party transactions totaled approximately $257,400 and $17,700 for the three months ended ~~March~~December 31, 2017 and 2016, respectively, and ~~$53,100~~$365,400 and $35,400 for the ~~nine~~six months ended ~~March~~December 31, 2017 and ~~2016.~~2016, respectively.

Certain significant shareholders, officers and directors of the Company participated as investors in the private ~~placement~~placements of the ~~Company's~~Company’s Series A Preferred, ~~in December 2016 (see Note 4).~~Series B Preferred and Series C Preferred. The terms of ~~the offering~~these offerings were reviewed and approved by ~~the~~ disinterested members of the ~~Company's~~Company’s Board of Directors who did not invest in the private ~~placement~~placements and who do not own any shares of Series A Preferred, Series B Preferred or Series C Preferred. ~~Details~~The affiliated investors participated in these offerings on terms that were no more favorable than the terms granted to unaffiliated investors.

Pursuant to the Company’s acquisition of Hausmann Industries, Inc. (“Hausmann”) in April 2017, the Company held back approximately$1,045,000 of the ~~private placement were~~purchase price. As of December 31, 2017, and June 30, 2017, the holdback liability to Hausmann under the purchase agreement was $1,000,000 and $1,045,000, respectively. Certain principals of Hausmann are holders of the Company’s Series B Preferred and one of the principals, David Hausmann, is an employee of the Company.

In connection with the Acquisition of B&C in October 2017, the Company held back approximately $647,000 in cash plus an earn-out payment of a minimum of $500,000 up to $1,500,000. These obligations to B&C, totaling approximately $2,147,000, are liabilities on the Company’s balance sheet as of December 31, 2017. In addition, the Company withheld approximately 467,000 shares of common stock to be released to B&C pursuant to the holdback provisions in the Asset Purchase Agreement. These shares are included in common stock on the ~~Company's Current Report on Form 8-K, filed with~~Company’s balance sheet at December 31, 2017. Certain principals of B&C are holders of the ~~Securities~~Company’s common stock and ~~Exchange Commission on January 3, 2017.~~two of the principals, Michael Cronin and Jason Anderson, are employees of the Company.

NOTE 9.8. LINE OF CREDIT

On ~~March 31,~~September 28, 2017, the Company modified its credit agreement with Bank of the West and entered into ~~a Loan and Security Agreement with a bank~~an Amended Credit Facility (the “Amended Credit Facility”) to provide asset-based financing to the Company to be used for funding the Acquisition ~~(see~~(see Note ~~11)~~2) and for operating capital. ~~This Loan and Security Agreement replaces the $1,000,000 line of credit previously put in place with an asset based lender in September, 2016.~~The ~~Company~~ ~~paid an early termination fee of $14,000 associated with that~~ ~~previous~~ ~~line of credit.~~

~~The Loan and Security Agreement~~Amended Credit Facility provides for revolving credit borrowings by the Company ~~in an amount~~ up to the lesser of ~~$8,000,000~~$11,000,000 or the calculated borrowing base. The borrowing base is computed monthly and is equal to the sum of stated percentages of eligible accounts receivable and inventory, less a reserve. Amounts outstanding bear interest at LIBOR plus 2.25%. The Company paid a commitment fee of .25% and the line is subject to an unused line fee of .25%. The maturity date is ~~two years from the date of the note.~~ ~~Obligations~~September 30, 2019. The Company’s obligations under the ~~Loan and Security Agreement~~Amended Credit Facility are secured by a first-priority security interest in substantially all of ~~the Company's~~ ~~assets.~~its assets, including those of its subsidiaries. The ~~Loan~~Amended Credit Facility includes financial covenants, such as ratios for consolidated leverage and ~~Security Agreement contains~~fixed charge coverage, and customary affirmative and negative covenants for a credit facility of this type, including, ~~covenants~~among others, the provision of annual, quarterly and monthly financial statements and compliance certificates, maintenance of property, insurance, compliance with laws and environmental matters, restrictions on incurrence of indebtedness, granting of liens, making investments and acquisitions, paying dividends, entering into affiliate transactions and asset sales. The Amended Credit Facility also contains penalties in connection with customary events of default, including, among others, payment, bankruptcy, representation and warranty, covenant, change in control, judgment and events or conditions that ~~restrict~~have a Material Adverse Effect (as defined in the ~~ability~~Amended Credit Facility). As of December 31, 2017, the Company had borrowed $6,742,979 under the Amended Credit Facility compared to $2,171,935 as of June 30, 2017. There was $1,874,268 available to borrow under the original loan and security agreement as of December 31, 2017.

NOTE 9. INCOME TAXES

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (“Tax Act”). The Tax Act provides for significant changes to the U.S. Internal Revenue Code of 1986, as amended. Among other items, the Act permanently reduces the federal corporate tax rate to 21% effective January 1, 2018. As the Company’s fiscal year end falls on June 30, the statutory federal corporate tax rate for fiscal 2018 will be prorated to 27.5%, with the statutory rate for fiscal 2019 and beyond at 21%.

As a result of the reduction in the corporate income tax rate from 35% to 21% under the Act, the Company revalued its net deferred tax assets at December 31, 2017. As of December 31, 2017 and ~~its subsidiaries~~June 30, 2017, a full valuation allowance has been established against net deferred tax assets. This resulted in no reported income tax expense associated with the operating profit reported during the three and six months ended December 31, 2017.

The final transition impacts of the Tax Act may vary from the current estimate, possibly materially, due to, among other things, ~~incur or guarantee indebtedness, incur liens, dispose of assets, engage in mergers~~further clarification and ~~consolidations, make acquisitions or other investments, make~~ changes in interpretations of the ~~nature~~Tax Act, any legislative action to address questions that arise because of ~~its business, and engage~~the Tax Act, any changes in ~~transactions with affiliates. The Loan and Security Agreement also contains financial covenants applicable~~accounting standards for income taxes or related interpretations in response to the ~~Company~~Tax Act, and ~~its subsidiaries, including a maximum monthly~~the completion of the Company’s consolidated ~~leverage and a minimum monthly consolidated fixed charge coverage ratio. As of March 31, 2017, the Company~~ ~~had borrowed approximately $2.5 million under the Loan and Security Agreement compared to no borrowings~~financial statements as of and for the year ending June 30, ~~2016. Management believes that cash balances, cash generated~~2018. In accordance with SAB 118, any necessary measurement adjustments will be recorded and disclosed within one year from ~~operating activities, and cash available pursuant to~~ the ~~line of credit will continue to be sufficient to meet~~enactment date within the ~~Company's annual operating requirements. The line of credit matures on April 1, 2019. Management expects to be able to renew this credit facility when it matures with~~period the ~~current lender or another lender.~~adjustments are determined.

NOTE 10. RECENT ACCOUNTING PRONOUNCEMENTS

Additionally, the SEC released Staff Accounting Bulletin No. 118 (“SAB 118”) which provides guidance on accounting for the Act’s impact under ASC Topic 740, Income Taxes (“ASC 740”). The guidance in SAB 118 addresses certain fact patterns where the accounting for changes in tax laws or tax rates under ASC 740 is incomplete upon issuance of an entity's financial statements for the reporting period in which the Act is enacted. Under the staff guidance in SAB 118, in the financial reporting period in which the Act is enacted, the income tax effects of the Act (i.e., only for those tax effects in which the accounting under ASC 740 is incomplete) would be reported as a provisional amount based on a reasonable estimate (to the extent a reasonable estimate can be determined), which would be subject to adjustment during a “measurement period” until the accounting under ASC 740 is complete. The measurement period is limited to no more than one year beyond the enactment date under the staff's guidance. SAB 118 also describes supplemental disclosures that should accompany the provisional amounts, including the reasons for the incomplete accounting, the additional information or analysis that is needed, and other information relevant to why the registrant was not able to complete the accounting required under ASC 740 in a timely manner. For discussion of the impacts of the Tax Act, refer to Note 9.

In November 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-14,Income Statement – Reporting Comprehensive Income (Topic 220), Revenue Recognition (Topic 605), and Revenue from Contracts with Customers (Topic 606): Amendments to SEC Paragraphs Pursuant to the Staff Accounting Bulletin (“SAB”) No. 116 and SEC Release No. 33-10403. This ASU amended, superseded and added certain SEC paragraphs in Topic 220, Topic 605 and Topic 606 to reflect the August 2017 issuance of SAB 116 and SEC Release No. 33-10403. The SEC staff issued SAB 116 to align its revenue guidance with Accounting Standards Codification (“ASC”) 606. For public business entities, this update is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early application is permitted. The Company is currently evaluating the impact of the adoption of this update on its consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11 – Earnings per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Part I of this update addresses the complexity of accounting for certain financial instruments with down round features. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Stakeholders asserted that accounting for freestanding and embedded instruments with down round features as liabilities subject to fair value measurement on an ongoing basis creates a significant reporting burden and unnecessary income statement volatility associated with changes in value of an entity’s own share price. That is, current accounting guidance requires changes in fair value of an instrument with a down round feature to be recognized in earnings for both increases and decreases in share price, even though an increase in share price will not cause a down round feature to be triggered and a decrease will cause an adjustment to the strike price only if and when an entity engages in a subsequent equity offering.

Part II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of the extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable non-controlling interests.

The amendments in Part I of this update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round features no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments in Part II of this update recharacterize the indefinite deferral of certain provisions of Topic 48 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. The Company is currently evaluating the impact the adoption of this update will have on its consolidated financial statements and disclosures. This amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018.

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350), Simplifying the Test for Goodwill Impairment. The amendment in this update simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. An entity should apply the amendments in this update on a prospective basis. This amendment will be effective for the Company in its fiscal year beginning July 1, 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company ~~is currently evaluating the impact the adoption~~has early adopted this standard as of ~~ASU 2017-04 will have on its consolidated financial statements and disclosures.~~July 1, 2017.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805), Clarifying the Definition of a Business. The Board issued this update to clarify the definition of a business with the objective of assisting entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. Under Topic 805, there are three elements of a business—inputs, processes, and outputs (collectively referred to as a ~~"set"~~“set”) although outputs are not required as an element of a business set. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business, reducing the number of transactions that need to be further evaluated. If the screen is not met, the amendments in this update:

require that a business set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output, and

remove the evaluation of whether a market participant could replace missing elements.

~~remove the evaluation of whether a market participant could replace missing elements.~~

The amendments provide a framework for evaluating whether both an input and a substantive process are present. Lastly, the amendments in this update narrow the definition of the term output so that the term is consistent with how outputs are described in Topic 606. This amendment will be effective for the Company in its fiscal year (including interim periods) beginning July 1, 2018. The Company is currently evaluating the impact the adoption of ASU 2017-01 will have on its consolidated financial statements and disclosures.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842,) a new guidance on leases. This guidance replaces the prior lease accounting guidance in its entirety. The underlying principle of the new standard is the recognition of lease assets and lease liabilities by lessees for substantially all leases, with an exception for leases with terms of less than twelve months. The standard also requires additional quantitative and qualitative disclosures. The guidance is effective for interim and annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The standard requires a modified retrospective approach, which includes several optional practical expedients. Accordingly, the standard is effective for the Company on July 1, 2019. The Company is currently evaluating the impact that this guidance will have on the consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments, a guidance related to financial instruments - overall recognition and measurement of financial assets and financial liabilities. The guidance enhances the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation and disclosure. The update to the standard is effective for public companies for interim and annual periods beginning after December 15, 2017. Accordingly, the standard is effective for the Company on July 1, 2018. The Company is currently evaluating the impact that the standard will have on the consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customer (Topic 606). This authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2017. Accordingly, the Company will adopt this guidance on July 1, 2018. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.

NOTE 11. SUBSEQUENT EVENTS

On March 21, 2017 the Company entered into a definitive agreement (the "Asset Purchase Agreement") to acquire substantially all the assets of Hausmann Industries, Inc., a New Jersey corporation ("Hausmann") for $10.0 million in cash, subject to adjustment, as provided in the Asset Purchase Agreement (the "Acquisition"). The Acquisition was effected through Hausmann Enterprises, LLC, a newly formed Utah limited liability company, wholly owned by the Company (the "Acquisition Subsidiary") and closed on April 3, 2017.

Financing for the Acquisition was provided by proceeds from the sale of equity securities in a private offering to accredited investor (the "Private Placement") and borrowings under the Loan and Security Agreement (see Note 9). Closing of the Private Placement occurred concurrently with the closing of the Acquisition. At the closing of the Acquisition, the Company paid Hausmann $9.0 million of the $10.0 million purchase price holding back $1.0 million for purposes of satisfying adjustments to the purchase price as may be required by the Asset Purchase Agreement and indemnification claims, if any. Subject to adjustments or claims as provided by the Asset Purchase Agreement, 25% of the holdback amount will be released to Hausmann on January 1, 2018, and the balance will be released to Hausmann 18 months after closing. As part of the Acquisition, the Company assumed certain liabilities and obligations of Hausmann related to its ongoing business (primarily trade accounts and similar obligations in the ordinary course).

In connection with the Acquisition, the Company sold equity securities for gross proceeds of $7,795,000 in the Private Placement pursuant to the terms of a Securities Purchase Agreement dated March 21, 2017 (the "Securities Purchase Agreement") entered into with certain accredited investors, including institutional investors (the "Investors"). The securities sold in the Private Placement were a total of 1,559,000 Units at $5.00 per Unit, each Unit made up of: (1) one share of common stock priced at $2.50 per share, (2) one share of the Company's newly designated, no par value share Series B Convertible Preferred Stock ("Series B Preferred") priced at $2.50 per share, and a common stock purchase warrant (the "Series B Warrants") to purchase 1.5 shares of common stock, exercisable at $2.75 per share for six years. Ladenburg Thalmann & Co. Inc. ("Ladenburg") acted as placement agent in connection with the Private Placement and the Company paid Ladenburg fees for its services for introducing Investors to the Company. In connection with the closing of the Private Placement, the Company agreed to file a registration statement with the SEC to register all shares of common stock issuable as part of the Units, as well as all shares of common stock underlying conversion of the Series B Preferred or payment of Series B ~~dividends~~ ~~or issuable upon exercise of the Series B Warrants. The Company filed a registration statement on~~ January ~~27, 2017 to fulfill these obligations and the registration statement became effective on February 10, 2017.~~

Also in connection with the Acquisition, Acquisition Subsidiary entered into an agreement with Hausmann to lease the 60,000 square-foot manufacturing and office facility in Northvale, New Jersey (the "Facility") effective as of April 3, 2017 (the "Lease") with an initial two-year term, annual lease payments of $360,000 for the first year, and 2% increases in each subsequent year. The Lease grants Acquisition Subsidiary two options to extend the term of the Lease for two years per extension term, subject to annual 2% per year increases in base rent, and a third option at the end of the second option term for an additional five-years at fair market value. The Company also offered employment to Hausmann's employees at closing including David Hausmann, the primary stockholder of Hausmann and its former principal executive officer. Mr. Hausmann entered into an employment agreement with the Company effective as of April 3, 2017 to assist in the transition of the acquired business.

~~In April 2017,~~2018, the Company paid approximately ~~$94,000~~$201,000 of preferred stock dividends with respect to the Series A Preferred and Series B Preferred that were accrued induring the ~~quarter~~three months ended ~~March~~December 31, 2017. The Company paid the dividends by issuing ~~32,975~~69,574 shares of common ~~stock and the payment of $15,600 cash.~~stock.

~~Item~~Item 2. ~~Management's~~Management’s Discussion and Analysis of Financial Condition and Results of Operations

~~Overview~~Cautionary Statement Concerning Forward-Looking Statements

Dynatronics Corporation ("Company," "Dynatronics," "we") designs, manufactures, distributes, markets and sells physical medicine and rehabilitation products. We offer a broad line of medical equipment including therapy devices, medical supplies and soft goods, treatment tables and rehabilitation equipment. We market and sell our products primarily to physical therapists, chiropractors, athletic trainers and sports medicine practitioners. We operate on a fiscal year ending June 30. For example, reference to fiscal year 2017 refers to the year ending June 30, 2017.

~~Recent Events~~

On March 21, 2017, we entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") to acquire substantially all the assets of Hausmann Industries, Inc., a New Jersey corporation ("Hausmann") for $10,000,000Information contained in cash, subject to adjustment (the "Acquisition"). The Acquisition was effected through Hausmann Enterprises, LLC, a newly formed Utah limited liability company, wholly owned by the Company (the "Acquisition Subsidiary"). We financed the Acquisition with proceeds from the sale of our equity securities in a private offering to accredited investors (the "Private Placement") and borrowings under an asset-based credit facility pursuant to a Loan and Security Agreement with Bank of the West (the "Loan and Security Agreement"). On April 3, 2017, we closed the Acquisition and took control of the assets and concurrently closed the Private Placement. We obtained funding under the credit facility on March 31, 2017. At the closing of the Acquisition, we paid Hausmann $9,000,000 of the $10,000,000 purchase price and retained $1,000,000 for purposes of satisfying adjustments to the purchase price as may be required by the Asset Purchase Agreement and indemnification claims, if any. Subject to adjustments or claims as provided by the Asset Purchase Agreement, 25% of the holdback amount will be released to Hausmann on January 1, 2018, and the balance will be released 18 months after closing. As part of the Acquisition transaction, we assumed certain liabilities and obligations of Hausmann related to its ongoing business (primarily trade accounts and similar obligations in the ordinary course of business).

In connection with the Acquisition, we entered into an agreement with Hausmann to lease the 60,000 square-foot manufacturing and office facility in Northvale, New Jersey (the "Facility") effective as of the closing date (the "Lease") with an initial two-year term, with annual lease payments of $360,000 for the first year, and 2% increases in each subsequent year. The Lease grants the Acquisition Subsidiary two options to extend the term of the lease for two years per extension term, subject to annual 2% per year increases in base rent, and a third option at the end of the second option term for an additional five years at fair market value. We also offered employment to Hausmann's employees at closing. David Hausmann, a principal stockholder and former principal executive officer of Hausmann, entered into an employment agreement with the Company and will assist in the transition of the acquired business.

The Loan and Security Agreement provides for revolving credit borrowings by the Company in an amount up to the lesser of $8,000,000 or a borrowing base computed as provided in the Loan and Security Agreement. The borrowing base is computed monthly and is equal to the sum of stated percentages of eligible accounts receivable and inventory, less a reserve. Amounts outstanding bear interest at LIBOR plus 2.25%. We paid a commitment fee of .25% to establish the credit facility and the line is subject to an unused line fee of .25%. The maturity date is two years from the date of the note. Our obligations under the Loan and Security Agreement are secured by a first-priority security interest in substantially all of our assets. The Loan and Security Agreement contains affirmative and negative covenants, including covenants that restrict our ability, among other things, to incur or guarantee indebtedness, incur liens, dispose of assets, engage in mergers and consolidations, make acquisitions or other investments, make changes in the nature of its business, and engage in transactions with affiliates. The Loan and Security Agreement also contains financial covenants applicable to the Company and our subsidiaries, including a maximum monthly consolidated leverage and a minimum monthly consolidated fixed charge coverage ratio.

In the Private Placement, we raised gross proceeds of $7,795,000 pursuant to the terms of a Securities Purchase Agreement dated March 21, 2017 (the "Securities Purchase Agreement") entered into with certain accredited investors, including institutional investors (the "Investors") for the issuance of 1,559,000 Units at $5.00 per Unit, each Unit made up of one share of our common stock, no par value per share ("Common Stock") at $2.50 per share, one share of our Series B Convertible Preferred Stock, no par value per share ("Series B Preferred Stock") at $2.50 per share, and a warrant to purchase 1.5 shares of Common Stock, exercisable at $2.75 per share for six years. Ladenburg Thalmann & Co. Inc. ("Ladenburg") acted as placement agent in connection with the Private Placement and we paid Ladenburg fees for its services for introducing Investors to the Company. In connection with the Private Placement, we also entered into a Registration Rights Agreement, obligating us to file a registration statement with the Securities and Exchange Commission to register all shares of Common Stock issuable as part of the Units, as well as all shares of Common Stock underlying conversion of the Series B Preferred Stock or payment of Series B Dividends or issuable upon exercise of the Warrants, within 45 days of the closing. On April 14, 2017, we filed a registration statement onthis Form ~~S-3 with the Securities and Exchange Commission to meet these registration obligations. The Securities and Exchange Commission declared that registration statement effective on April 24, 2017.~~

~~Business Outlook~~

Our strategic direction is to accelerate growth both organically and by acquisition. In support of this strategy, we completed the Acquisition of the assets of Hausmann in April 2017, the corresponding $8,000,000 Loan and Security Agreement and $7,795,000 Private Placement, as well as a private placement of $5,000,000 of Series A 8% Convertible Preferred Stock ("Series A Preferred") led by affiliates of Prettybrook Partners LLC (collectively, "Prettybrook") in June 2015 and December 2016. We believe the Acquisition improves our market position and will improve our operating results and position us for positive cash flow. The debt and equity financings described above help to strengthen our financial position and provide operating capital. We believe our relationship with Prettybrook provides us with strategic and financial resources that will facilitate the execution of our strategic objectives.

Our merger and acquisition ("M&A") strategy is focused on acquiring complementary businesses that simultaneously meet our investment criteria and enhance our product offering. We are evaluating multiple acquisition opportunities and aim to execute on at least one more acquisition in fiscal year 2018. We believe this strategy will leverage our unique distribution channel with high quality products that will increase sales and profitability and/or expand our distribution reach and product offering further strengthening our position in the market.

Our strategy is also focused on growing organically, both in the U.S. and internationally. We previously began implementing a plan to add new dealers and sales representatives to expand our coverage across North America and into international territories. Under the direction of our Senior Vice-President of Sales and Marketing hired in March 2016, we have reorganized our sales management team, adding a new Director of International Sales, a new Eastern Region Sales Manager, and a Director of Clinical Education. The sales organization is also a key element of our M&A integration strategy.

Dynatronics is a leader in product innovation and product quality. In fiscal year 2017, we successfully launched several new or updated products. The strategy for introducing technologically updated or new products continues to be a core emphasis for the Company, including both proprietary and OEM products. We expect that our continued introduction of new products will reinforce our reputation as an innovator of quality products and further strengthen our position as a leader in the design and manufacture of therapeutic modalities.

As delivery of healthcare in the U.S. progresses under legislative reform, we believe there will be increasing demand for rehabilitation and physical therapy products and services. There is increasing pressure to find alternatives to the surgical suite. We believe this will lead to more demand for physical therapy services as a method for avoiding, preventing or delaying the need for surgical interventions. There are orthopedic clinics now embedding physical therapy within their offering of services in order to better address patient needs in a pre-surgical as well as post-surgical environment. Third-party payers are also demanding better outcomes and structuring reimbursement conventions to reward practitioners who show identifiably improved outcomes. Physical therapy has always figured prominently in the post-surgical environment to achieve the best outcomes following orthopedic surgical procedures. With the new reimbursement paradigms, the importance of physical therapy will only increase. The concept of "pre-habilitation" to avoid, prevent or delay surgical interventions, combined with traditional rehabilitation to achieve the best post-surgical outcomes provides a positive environment for growth of physical therapy services and products in the future.

~~We also service the athletic training market. The growth of college athletics –~~10-Q, particularly in the "Power Five" conferences – is creating a demand for the best and most impressive training facilities. We are working to tap into that demand by offering our custom designed furniture and proprietary products. The acquisition of Hausmann will particularly boost this effort as it has historically had success with its ProTeam^TM ~~line of products that address this same market.~~

~~In summary, based on our defined strategic initiatives we are focusing our resources in the~~ following ~~areas:~~

·	~~Updating and improving our selling and marketing efforts including new sales management, new reporting tools, and focusing our sales and marketing efforts into our core markets;~~

·	Seeking to improve distribution of our products through recruitment of additional qualified sales representatives and dealers attracted by the many new products being offered and expanding the availability of proprietary combination therapy devices;

·	~~Improving gross profit margins by, among other initiatives, increasing market share of manufactured products with emphasis on our state-of-the-art Dynatron~~^® ~~ThermoStim probe, Dynatron Solaris~~^® ~~Plus and 25 Series~~^™ ~~products as well as new OEM products from other manufacturers, both domestic and foreign.~~

·	Maintaining our position as a technological leader and innovator in our markets through the promotion of new products introduced during the current fiscal year and seeking for opportunities to introduce other new products during the new fiscal year;

·	Increasing international sales by (1) identifying appropriate distributors for the approved products, (2) finalizing regulatory approvals in countries where expansion is deemed desirable, and (3) further developing relationships with existing distributors in countries such as Japan in order to increase sales in those countries where products are approved;

·	Exploring strategic business acquisitions. This will leverage and complement our competitive strengths, increase market reach and allow us to ultimately broaden our footprint in the physical medicine markets;

·	~~Attending strategic conferences to make investors aware of our strategic plans, attract new capital to support the business development strategy and identify other acquisition targets.~~

~~Results of Operations~~

The following discussion and analysis of our financial condition and results of operations for the three and nine months ended March 31, 2017, should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto appearing in Part I, Item 1 of this report, and our Annual Report on Form 10-K for the fiscal year ended June 30, 2016, as amended, which includes audited financial statements for the year then ended. We have rounded many numbers to the nearest thousand dollars in this analysis. These numbers should be read as approximate. Results of operations for the third fiscal quarter and nine months ended March 31, 2017, are not necessarily indicative of the results that may be achieved for the full fiscal year ending June 30, 2017. Our results of operations in future periods will include the impact of our Acquisition of Hausmann on April 3, 2017. In connection with the Acqusition and related developments, we filed a Current Report on Form 8-K on March 22, 2017 and another on April 4, 2017, which was amended on April 14, 2017.

~~Net Sales~~

~~Net sales increased 4.1% or $307,000, to $7,716,000 for the quarter ended March 31, 2017, compared to net sales of $7,409,000 for the quarter ended March 31, 2016.~~ The 4.1% year-over-year increase in net sales for the quarter was attributable to: (1) a 14% increase in sales of therapeutic modalities supported in large part by the introduction of new products, including a short wave diathermy device manufactured for Dynatronics by a European manufacturer; and (2) a 13% increase in sales of distributed capital equipment (capital equipment manufactured by other manufacturers). These gains were partially offset by decreases in sales of manufactured capital equipment and distributed supplies.

For the nine months ended March 31, 2017, net sales increased $2,311,000 or 10.4% to $24,592,000, compared to net sales of $22,281,000 for the corresponding period ended March 31, 2016. The 10.4% increase in sales was achieved primarily by increases in sales of distributed capital equipment, which, as explained above, are products distributed by us but not manufactured by or manufactured specifically for us. Much of this increase in distributed capital equipment is the result of increased sales in the long term care markets which has been a focus for the Company this past year. We anticipate experiencing increasing demand for our higher margin manufactured and OEM products as we develop more strategic and focused marketing programs emphasizing sales of those products.

~~Gross Profit~~

~~Gross profit for the~~ ~~quarter ended March 31, 2017 increased $215,000, or about 8.7%, to $2,702,000, or 35.0% of net sales. By comparison, gross profit for the quarter ended~~ ~~March 31, 2016 was $2,486,000, or 33.6% of net sales~~. The increase in gross margin percentage was driven by the increased sales of therapeutic modalities that carry a higher gross margin than other product categories. Increases in gross profit dollars included $174,000 and $97,000, respectively, on sales of therapeutic modalities and distributed capital, partially offset by reductions of sales and gross profit in other product categories.

Gross profit for the nine months ended March 31, 2017 increased $896,000 or about 11.7% to $8,570,000, or 34.8% of net sales, compared to gross profit for the nine months ended March 31, 2016 of $7,674,000, or 34.4% of net sales. The increases in gross profit dollars included $545,000 from increased sales of distributed capital equipment and $213,000 from increased sales of therapeutic modalities. The gross margin percentage increased modestly driven by the higher margin on therapeutic modalities, offset by lower margins on distributed capital.

~~Selling, General and Administrative Expenses~~

Selling, general and administrative ("SG&A") expenses increased 20.3%, or $533,000, to $3,153,000 for the quarter ended March 31, 2017, compared to $2,620,000 for the quarter ended March 31, 2016. SG&A expenses for the nine months ended March 31, 2017 increased 17.8%, or $1,324,000, to $8,769,000 compared to $7,445,000 for the nine months ended March 31, 2016.

Increases in selling expenses for the quarter ended March 31, 2017, in comparison to the same period of the prior year, were $118,000 of the $533,000 increase in SG&A expenses. The increases in selling expenses include: (1) $115,000 in higher personnel costs associated with hiring additional sales management and marketing personnel to implement our plans for organic growth; (2) $29,000 associated with our digital marketing program; and (3) $38,000 in trade show and travel expenses. These increases were offset by a $64,000 reduction in sales commissions and other selling related expenses. Increases in selling expenses for the nine months ended March 31, 2017, compared to the same period of 2016, were $554,000 of the $1,324,000 increase in SG&A. The nine month increases in selling expenses include: (1) $368,000 in higher personnel costs associated with hiring additional sales management and marketing personnel; (2) $83,000 associated with our digital marketing program; and (3) $78,000 in trade show and travel expenses.

Increases in general and administrative expenses for the quarter ended March 31, 2017, in comparison to the same quarter of 2016, were $415,000 of the $533,000 increase in SG&A expenses. The increase in general and administrative expenses included $486,000 of acquisition related costs in the quarter ended March 31, 2017 representing a $450,000 increase compared to the same quarter of the prior year. For the nine months ended March 31, 2017, year-over-year increases in general and administrative expenses were $770,000 of the $1,324,000 increase in SG&A expense. This increase was driven primarily by acquisition costs of $533,000, representing a $489,000 increase over prior year, and increased labor and benefits of $296,000. The higher labor and benefits were mostly related to expenses at our Tennessee operation in the first half of fiscal 2017. Management changes at that facility are returning labor expenses to more historical norms through the second half of the fiscal year.

~~Research and Development Expenses~~

Research and development ("R&D") expenses for the quarter ended March 31, 2017 decreased 7.8%, or $19,000, to $231,000 compared to $250,000 in the quarter ended March 31, 2016. R&D expenses for the nine months ended March 31, 2017 increased 6.5%, or $50,000, to $819,000 compared to $769,000 in the nine months ended March 31, 2016. The increase in R&D expenses for the nine-month period are related to new products already introduced during the year and products yet to be introduced in the next quarter. New product development is an important part of our strategy to capture market share and increase sales. R&D costs are expensed as incurred and are expected to remain approximately at present levels in the current fiscal year.

~~Loss Before Income Tax~~

~~Pre-tax loss for the quarter ended March 31, 2017 was $755,000 compared to pre-tax loss of $451,000 for the quarter ended March 31, 2016.~~ The $304,000 increase in pre-tax loss for the current year quarter was primarily attributable to $450,000 in increased acquisition related expenses, partially offset by $215,000 of higher gross profits.

Pre-tax loss for the nine months ended March 31, 2017 was $1,136,000 compared to pre- tax loss of $757,000 for the nine months ended March 31, 2016. The $379,000 increase in pre-tax loss for the nine months ended March 31, 2017 was primarily attributable to $554,000 in higher selling and marketing costs, $489,000 in higher acquisition related expenses, and $296,000 in increased labor and benefits, partially offset by $896,000 in higher gross profit.

~~Income Tax Provision (Benefit)~~

Income tax provision was $0 for both the quarter and nine months ended March 31, 2017, respectively. This compares to income tax provision of $0 for the quarter and nine months ended March 31, 2016, respectively. We increased the valuation allowance on our net deferred income tax assets by $276,000 and $410,000 for the quarter and nine months ended March 31, 2017, respectively, eliminating any tax benefit that would have otherwise been recognized. See "~~Liquidity and Capital Resources – Deferred Income Tax Assets"~~ ~~below for more information regarding the valuation allowance and its anticipated impact on the effective tax rate for fiscal year 2017.~~

~~Net Loss~~

Net loss was $755,000 for the quarter ended March 31, 2017, compared to a net loss of $451,000 for the quarter ended March 31, 2016. Net loss was $1,136,000 for the nine months ended March 31, 2017, compared to $757,000 for the nine month period ended March 31, 2016. The changes in net loss are the same as explained above for ~~Loss Before Income Tax~~.

~~Net Loss Applicable to Common Stockholders~~

Net loss applicable to common stockholders was $849,000 ($0.28 per share) for the quarter ended March 31, 2017, compared to $531,000 ($0.19 per share) for the quarter ended March 31, 2016. The increase in net loss applicable to common stockholders for the quarter ended March 31, 2017 is primarily due to the factors explained above for ~~Loss Before Income Tax~~.

Net loss applicable to common stockholders was $1,783,000 ($0.61 per share) for the nine months ended March 31, 2017, compared to $998,000 ($0.37 per share) for the nine months ended March 31, 2016. The higher net loss applicable to common stockholders for the nine months ended March 31, 2017 is primarily due to the factors explained above for ~~Loss Before Income Tax~~ plus a $376,000 non-cash deemed dividend associated with the issuance of 390,000 shares of Series A Preferred in December 2016. The deemed dividend reflects the difference between the underlying common share value of the 390,000 shares of Series A Preferred as if converted, based on the closing price of the Company's common stock on the date of the transaction (December 28, 2016), less an amount of the purchase price assigned to the Series A Preferred in an allocation of the purchase price between the Series A Preferred and the common stock purchase warrants that were issued with the Series A Preferred.

Net loss applicable to common stockholders includes the impact of accrued dividends to holders of the Series A Preferred which were $94,000 for the quarter ended March 31, 2017 compared to $81,000 for the same quarter of 2016. For the nine months ended March 31, 2017, the accrued dividends to holders of the Series A Preferred were $272,000 compared to $242,000 for same period of the prior year. The increase in dividends reflects the issuance of additional Series A Preferred shares in December 2016. We subsequently paid all of the these accrued dividends by issuing shares of our common stock, except we paid $15,600 and $16,240, respectively, in cash for dividends accrued in the quarter and nine months ended March 31, 2017. The cash payments related to a portion of the dividends accrued on the shares of Series A Preferred issued December 28, 2016.

~~Liquidity and Capital Resources~~

~~We have historically~~ financed operations through cash from operations, available cash reserves, borrowings under a line of credit facility, and sales of equity securities. On March 31, 2017, we entered into a new two year loan and security agreement with Bank of the West (the "Loan and Security Agreement") for an asset based lending facility for up to the lesser of $8,000,000 or an amount available based upon a borrowing base calculation established in the agreement. We expect to obtain capital for future acquisitions using proceeds from debt and equity offerings. Working capital was $5,778,000 as of March 31, 2017, inclusive of the current portion of long-term obligations and credit facilities, compared to working capital of $5,820,000 as of June 30, 2016. The current ratio was 1.9 to 1 as of March 31, 2017 and 2.5 to 1 as of June 30, 2016.

~~Cash and Cash Equivalents~~

Our cash and cash equivalents position as of March 31, 2017, was $3,353,000 compared to cash and cash equivalents of $966,000 as of June 30, 2016. The primary sources of cash in the nine months ended March 31, 2017 were borrowings under the new line of credit of $2,500,000 in March 2017 and net proceeds of approximately $929,000 from the sale of Series A Preferred and warrants in December 2016.

~~Accounts Receivable~~

Trade accounts receivable, net of allowance for doubtful accounts, decreased 17.0% to $2,925,000 as of March 31, 2017, from $3,524,000 as of June 30, 2016. The decrease is primarily due to collection activities that reduced the average age of accounts receivable. Trade accounts receivable represent amounts due from our customers including medical practitioners, clinics, hospitals, colleges and universities and sports teams as well as dealers and distributors that purchase our products for redistribution. We believe that our estimate of the allowance for doubtful accounts is adequate based on our historical knowledge and relationship with our customers. Accounts receivable are generally collected within approximately 30 days of invoicing.

~~Inventories~~

Inventories, net of reserves, increased $786,000, or 15.7%, to $5,783,000 as of March 31, 2017, compared to $4,997,000 as of June 30, 2016. Inventory levels fluctuate based on the timing of large inventory purchases from domestic and overseas suppliers as well as increased parts related to new products being planned for introduction. We believe that our estimate of the allowance for inventory reserves is adequate based on our historical knowledge and product sales trends.

~~Accounts Payable~~

Accounts payable increased $575,000, or 30.1%, to $2,490,000 as of March 31, 2017, from $1,914,000 as of June 30, 2016. The increase in accounts payable for the nine months ended March 31, 2017 was primarily related to an increase in the average time to pay suppliers.

~~Line of Credit~~

On March 31, 2017, we entered into the Loan and Security Agreement with Bank of the West to provide asset-based financing to the Company to be used for funding the Acquisition and for operating capital. This Loan and Security Agreement replaces the $1,000,000 line of credit previously put in place with an asset based lender in September, 2016, which we closed prior to this transaction by the payment of a $14,000 early termination fee.

The Loan and Security Agreement provides for revolving credit borrowings by the Company in an amount up to the lesser of $8,000,000 or the calculated borrowing base. The borrowing base is computed monthly and is equal to the sum of stated percentages of eligible accounts receivable and inventory, less a reserve. Amounts outstanding bear interest at LIBOR plus 2.25%. We paid a commitment fee of .25% and the line is subject to an unused line fee of .25%. The maturity date is two years from the date of the note. Our obligations under the Loan and Security Agreement are secured by a first-priority security interest in substantially all of our assets. The Loan and Security Agreement contains affirmative and negative covenants, including covenants that restrict the ability of the Company and its subsidiaries to, among other things, incur or guarantee indebtedness, incur liens, dispose of assets, engage in mergers and consolidations, make acquisitions or other investments, make changes in the nature of its business, and engage in transactions with affiliates. The Loan and Security Agreement also contains financial covenants applicable to the Company and its subsidiaries, including a maximum monthly consolidated leverage and a minimum monthly consolidated fixed charge coverage ratio. As of March 31, 2017, we had borrowed approximately $2,500,000 under the Loan and Security Agreement compared to no borrowings as of June 30, 2016.

~~Debt~~

Long-term debt, excluding current installments, decreased $56,000 to $497,000 as of March 31, 2017, compared to $553,000 as of June 30, 2016. Our long-term debt is comprised primarily of a mortgage loan on our office and manufacturing facility in Tennessee. The principal balance on the mortgage loan is $540,000, of which $412,000 is classified as long-term debt, with monthly principal and interest payments of $13,278. Our mortgage loan matures in 2021.

In conjunction with the sale and leaseback of our corporate headquarters in August 2014, we entered into a $3,800,000 capital lease for a 15-year term with an investor group. Amortization associated with that lease is recorded on a straight line basis over 15 years. Lease payments of approximately $28,000 are payable monthly. Total amortization expense related to the leased building is approximately $25,000 and $75,000 (both net of amortized gain on sale) for the quarter and nine months ended March 31, 2017, respectively. The deferred gain on sale is being amortized over the 15-year life of the lease. Total imputed interest related to the leased building is approximately $47,000 and $143,000 for the quarter and nine months ended March 31, 2017, respectively.

~~Deferred Income Tax Assets~~

We have determined that we do not meet the "more likely than not" threshold that deferred income tax assets will be realized. Accordingly, a valuation allowance is required. Any reversal of the valuation allowance in future periods will favorably impact the Company's results of operations in the period of reversal.

~~At March 31, 2017 and June 30, 2016, we recorded a full valuation allowance against our net deferred income tax assets.~~

Deferred income tax assets and the related valuation allowance were increased by an estimated $276,000 and $410,000 for the quarter and nine months ended March 31, 2017, respectively. This resulted in no reported income tax benefit associated with the operating losses reported during the quarter and nine months ended March 31, 2017.

~~The Company's federal and state income tax returns for June 30, 2014, 2015, and 2016 are open tax years.~~

~~Inflation~~

~~Our revenues and net income have not been unusually affected by inflation or price increases for raw materials and parts from vendors.~~

~~Off-Balance Sheet Arrangements~~

~~None~~

~~Critical Accounting Policies~~

The preparation of our financial statements requires that we make estimates and judgments. We base these on historical experience and on other assumptions that we believe to be reasonable. Our critical accounting policies are discussed in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, ~~of our Annual Report on Form 10-K for the year ended June 30, 2016, as amended. There have been no material changes~~includes statements considered to ~~the critical accounting policies previously disclosed in that report.~~

~~Cautionary Statement Concerning Forward-Looking Statements~~

The statements contained in this Form 10-Q, particularly the foregoing discussion in Part I, Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations, that are not purely historical, are "forward-looking statements"be “forward-looking statements” within the safe harbors provided by Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, ("as amended (“Exchange ~~Act"~~Act”). These statements refer to our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of words or phrases such as ~~"believes," "expects," "anticipates," "should," "plans," "estimates," "intends,"~~“believes,” “expects,” “anticipates,” “should,” “plans,” “estimates,” “intends,” and ~~"potential,"~~“potential,” among others. Forward-looking statements include, but are not limited to, statements regarding product development, market acceptance, financial performance, revenue and expense levels in the future and the sufficiency of existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements, except as required by law.

Overview

Dynatronics Corporation (“Company,” “Dynatronics,” “we”) designs, manufactures and distributes advanced-technology therapeutic medical devices, therapeutic and medical treatment tables, rehabilitation equipment, custom athletic training treatment tables and equipment, institutional cabinetry, orthopedic soft goods, as well as other rehabilitation and therapy products and supplies. Through our various distribution channels, we market and sell our products to physical therapists, chiropractors, athletic trainers, sports medicine practitioners, orthopedists, and other medical professionals, hospitals, and institutions. We operate on a fiscal year ending June 30. For example, reference to fiscal year 2018 refers to the year ending June 30, 2018.

Recent Events

On November 29, 2017, we held our annual meeting of shareholders who approved the automatic conversion of the Series C Preferred and the Series D Preferred to common stock, subject, in the case of the Series C Preferred, to the right of the holder to elect to continue to hold the Series C Preferred and defer conversion subject to beneficial ownership limitation provisions. These unconverted shares of Series C Preferred are non-voting and are no longer entitled to certain preferences of the Series C Preferred Stock such as the accrual or receipt of dividends, liquidation preferences and redemption rights, and are treated as common shares for such purposes.

Business Outlook

Our strategic objective is to accelerate growth both organically and by acquisition. We acquired the assets of Hausmann Industries, Inc. (“Hausmann”) in April 2017 and we acquired the assets of Bird & Cronin, Inc. (“Bird & Cronin”) in October 2017. These acquisitions have enhanced our market position and improved our operating results, positioning us for positive cash flow.

The debt and equity financings completed in connection with these acquisitions strengthened our financial position and provided operating capital. We believe our relationships with Prettybrook Partners LLC and Bank of the West provide us with strategic and financial resources that will facilitate the execution of our strategic objectives.

In the past three years we have invested in executive talent and infrastructure to organize and prepare for additional significant growth. We have added executive talent across the organization including sales, operations, finance, and information technology. The management additions have bolstered our capacity to successfully acquire and integrate additional acquisition targets and to drive improvement in operating results in our current operations.

Our acquisition strategy is focused on acquiring complementary businesses that meet our investment criteria and broaden our product offerings. We continue to evaluate a variety of acquisition opportunities. Our target is to execute on at least one acquisition in calendar 2018.

Organic growth is also an essential element of our growth plan. Each operational division has established strategic plans to stimulate growth through expansion of distribution channels, product innovation or specific initiatives with existing customer base.

As delivery of healthcare in the U.S. progresses under legislative reform, we believe there will be increasing demand for rehabilitation and physical therapy products and services. There is increasing pressure to find alternatives to the surgical suite. We believe this will lead to more demand for physical therapy services as a method for avoiding, preventing or delaying the need for surgical interventions. There are orthopedic clinics now embedding physical therapy and rehabilitation within their offering of services in order to better address patient needs in a pre-surgical as well as post-surgical environment. Third-party payers are also demanding better outcomes and structuring reimbursement conventions to reward practitioners who show identifiably improved outcomes. Physical therapy and rehabilitation has always figured prominently in the post-surgical environment to achieve the best outcomes following orthopedic surgical procedures. With the new reimbursement paradigms, the importance of physical therapy will only increase. The concept of “pre-habilitation” to avoid, prevent or delay surgical interventions, combined with traditional rehabilitation to achieve the best post-surgical outcomes provides a positive environment for growth of physical therapy and rehabilitation services and products in the future.

We also service the athletic training market. The growth of college athletics – particularly in the “Power Five” conferences – is creating a demand for the best and most impressive training facilities. We are working to tap into that demand by offering our custom designed furniture and proprietary products. The acquisition of Hausmann will particularly boost this effort as it has historically had success with its ProTeam™ line of products that address this same market.

In summary, based on our defined strategic initiatives we are focusing our resources in the following areas:

●

Joining resources of the acquired entities to maximize cross-selling opportunities without disrupting each entity’s current channels of distribution;

●

Exploring operating synergies with acquired companies while respecting established operating paradigms at each operation;

●

Seeking to improve distribution of our products through expansion of sales channels;

●

Improving gross profit margins by, among other initiatives, increasing market share of manufactured products with emphasis on our high margin therapeutic modalities including state-of-the-art Dynatron® ThermoStim probe, Dynatron Solaris® Plus and 25 Series™ products as well as new products from other manufacturers such as Zimmer;

●

Maintaining our position as a technological leader and innovator in our markets through the promotion of new products introduced over the last year and seeking opportunities to introduce other new products during the current fiscal year;

●

Exploring strategic business acquisitions. This will leverage and complement our competitive strengths, increase market reach and allow us to ultimately broaden our footprint in the physical medicine markets; and

●

Attending appropriate investor conferences to better publicize our strategic plans, attract new capital to support the business development strategy and identify other acquisition targets.

Results of Operations

The following discussion and analysis of our financial condition and results of operations for the three and six months ended December 31, 2017, should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto appearing in Part I, Item 1 of this report, and our Annual Report on Form 10-K for the fiscal year ended June 30, 2017, which includes audited financial statements for the year then ended. We have rounded many numbers to the nearest thousand dollars in this analysis. These numbers should be read as approximate. Results of operations for the second fiscal quarter and six months ended December 31, 2017, are not necessarily indicative of the results that may be achieved for the full fiscal year ending June 30, 2018. This quarterly report includes the financial results of the newly acquired Bird and Cronin division. In connection with that acquisition, we filed a Current Report on Form 8-K on October 6, 2017.

Net Sales

Net sales increased $9,368,000, or 107.5%, to $18,081,000 for the quarter ended December 31, 2017, compared to net sales of $8,713,000 for the quarter ended December 31, 2016. The year-over-year increase in net sales for the quarter ended December 31, 2017 was driven by our acquisitions of Hausmann in April 2017 and Bird & Cronin in October 2017, that contributed $4,368,000 and $5,698,000, respectively, in net sales in the quarter ended December 31, 2017. These increases were partially offset by a decrease of approximately $699,000, or 8.0%, in net sales from Dynatronics’ legacy operations. Included in the quarter ended December 31, 2016 was a $517,000 non-recurring order that accounts for the majority of the $699,000 sales differential between the two comparative quarters.

For the six months ended December 31, 2017, net sales increased $14,003,000, or 83.0%, to $30,879,000, compared to net sales of $16,876,000 for the corresponding period ended December 31, 2016. The year-over-year increase in net sales was attributable primarily to the acquisitions of Hausmann and Bird & Cronin. Hausmann contributed net sales of $9,040,000 in the six months ended December 31, 2017 and Bird & Cronin contributed net sales of $5,698,000 in the three months ended December 31, 2017. These increases were partially offset by a decrease of approximately $731,000, or 4.3%, in net sales from Dynatronics’ legacy operations, primarily due to the $517,000 order in the second quarter of fiscal 2017 that did not repeat in the second quarter of fiscal 2018.

Gross Profit

Gross profit for the quarter ended December 31, 2017 increased $2,697,000, or about 87.7%, to $5,770,000, or 31.9% of net sales. By comparison, gross profit for the quarter ended December 31, 2016 was $3,073,000, or 35.3% of net sales. The year-over-year increase in gross profit was attributable to the acquisitions of Hausmann and Bird & Cronin that contributed $1,066,000 and $2,082,000, respectively, in gross profit in the quarter ended December 31, 2017. These increases were partially offset by a decrease of approximately $451,000 in Dynatronics’ legacy operations gross profit. That decrease was primarily attributable to lower sales which accounted for approximately $236,000 lower gross profit and reduced gross margin percentage resulting in $215,000 lower gross profit. The year-over-year decrease in gross margin percentage to 31.9% from 35.3% was due primarily to inclusion of Hausmann sales, which had a lower gross margin percentage in the quarter, as well as reduced gross margin in Dynatronics’ legacy operations, primarily attributable to reduced margins on freight charged to customers.

Gross profit for the six months ended December 31, 2017 increased $4,241,000, or about 72.3% to $10,109,000, or 32.7%, of net sales, compared to gross profit for the six months ended December 31, 2016 of $5,868,000, or 34.8% of net sales. The year-over-year increase in gross profit was driven by the acquisitions of Hausmann and Bird & Cronin that contributed $2,685,000 and $2,082,000, respectively, in gross profit in the six months ended December 31, 2017. These increases were partially offset by a decrease of approximately $525,000 gross profit in Dynatronics’ legacy operations, primarily attributable to lower sales which accounted for approximately $171,000 lower gross profit and reduced gross margin percentage resulting in $354,000 lower gross profit. The year-over-year decrease in gross margin percentage to 32.7% from 34.8% was due primarily to the inclusion of Hausmann lower gross margin percentage as well as reduced gross margin in Dynatronics’ legacy operations, primarily attributable to reduced margins on freight charged to customers.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses increased $2,259,000, or 79.2%, to $5,110,000 for the quarter ended December 31, 2017, compared to $2,851,000 for the quarter ended December 31, 2016. Selling expenses in the current quarter represented $691,000 of the $2,259,000 increase in SG&A expenses. Increases in selling expenses included the addition of $858,000 of expenses associated with Hausmann and Bird & Cronin operations, partially offset by $167,000 lower selling costs in Dynatronics’ legacy operations comprised primarily of reduced commissions on lower sales. General and administrative (“G&A”) expenses represented $1,567,000 of the $2,259,000 increase in SG&A expenses for the quarter ended December 31, 2017. Increases in G&A expenses included the addition of $1,623,000 in G&A expenses from Hausmann’s and Bird & Cronin’s operations, partially offset by $56,000 in decreased G&A expenses in Dynatronics’ legacy operations. G&A expenses included approximately $100,000 in acquisition related expenses during the current quarter.

SG&A expenses for the six months ended December 31, 2017 increased $3,317,000, or 59.1%, to $8,933,000, compared to $5,616,000 for the six months ended December 31, 2016. Selling expenses represented $968,000 of the $3,317,000 increase in SG&A expenses. Included in selling expenses were $1,169,000 of selling expenses associated with Hausmann and Bird & Cronin operations, partially offset by $202,000 lower selling costs in Dynatronics’ legacy operations comprised primarily of lower commissions on lower sales. G&A expenses represented $2,349,000 of the $3,317,000 increase in SG&A expenses for the six months ended December 31, 2017. Included in G&A expenses were $2,263,000 from Hausmann’s operations and Bird & Cronin’s operations, and $86,000 from Dynatronics’ legacy operations. G&A expenses included $314,000 in acquisition expenses in the six months ended December 31, 2017.

Research and Development Expenses

Research and development expenses for the quarter ended December 31, 2017 increased $244,000, or 78.8%, to $553,000 from approximately $309,000 in the quarter ended December 31, 2016. Research and development expenses for the six months ended December 31, 2017 increased $217,000, or 36.9%, to $805,000 from approximately $588,000 in the six months ended December 31, 2016. The increases in both the quarter and six months ended December 31, 2017 were driven by $325,000 in costs incurred on a project which was abandoned during the quarter ended December 31, 2017, offset by a reduction in other R&D expenses of approximately $81,000 and $108,000 for the quarter and six months, respectively, ended December 31, 2017.

Net Income (Loss) Before Income Tax

Pre-tax income for the quarter ended December 31, 2017 was approximately $14,000, compared to a pre-tax loss of $95,000 for the quarter ended December 31, 2016. The $109,000 improvement in pre-tax income for the quarter was primarily attributable to $2,697,000 higher gross profit, offset by $2,259,000 increased SG&A expenses and $244,000 higher research and development expenses. Pre-tax income for the six months ended December 31, 2017 was approximately $213,000, compared to a pre-tax loss of $381,000 for the six months ended December 31, 2016. The $594,000 improvement in pre-tax income for the six months was primarily attributable to $4,241,000 higher gross profit, offset by $3,317,000 in increased SG&A expenses and $217,000 higher research and development expenses. These changes in both the quarter and six months ended December 31, 2017 were primarily attributable to components of Hausmann’s and Bird & Cronin’s results of operations offset by the $325,000 in costs related to the abandoned project in the second fiscal quarter and transaction related costs of $100,000 and $314,000 in the quarter and six months ended December 31, 2017, respectively.

Income Tax Provision (Benefit)

Income tax provision was $0 for both the quarter and six months ended December 31, 2017, respectively. This compares to income tax provision of $0 for the quarter and six months ended December 31, 2016, respectively. We decreased the valuation allowance on our net deferred income tax assets equal to the one-time revaluation of our net deferred tax assets at the lower tax rate.

Net Income (Loss)

Net income was $14,000 for the quarter ended December 31, 2017, compared to a net loss of $95,000 for the quarter ended December 31, 2016. Net income was $213,000 for the six months ended December 31, 2017, compared to a net loss of $381,000 for the six months ended December 31, 2016. The changes in net income (loss) are the same as explained above for Net Income (Loss) Before Income Tax.

Net Loss Attributable to Common Stockholders

Net loss attributable to common stockholders was $1,314,916 ($0.23 per share) for the quarter ended December 31, 2017, compared to $560,000 ($0.19 per share) for the quarter ended December 31, 2016. The $755,000 year-over-year increase in net loss attributable to common stockholders is due to approximately $217,000 of additional preferred stock dividends associated with 390,000 shares of Series A Preferred Stock issued in December 2016, 1,559,000 shares of Series B Preferred issued in April 2017, and 2,800,000 of Series C Preferred shares and 1,581,935 shares of Series D Preferred Shares issued in October 2017. The increase was also attributable to approximately $454,000 in additional deemed dividends and approximately $194,000 in accretion of discounts associated with the Series C Preferred shares and warrants issued in connection with the Bird & Cronin Acquisition in comparison to deemed dividends associated with Series A Preferred in December 2016. These increases were partially offset by $109,000 in higher net income in the quarter ended December 31, 2017, compared to the same quarter of the prior year.

Net loss attributable to common stockholders increased $368,000 to $1,303,330 ($0.25 per share) for the six months ended December 31, 2017, compared to $935,000 ($0.33 per share) for the six months ended December 31, 2016. The decrease in net loss is due to approximately $594,000 in higher net income in the six months ended December 31, 2017, compared to the same period of the prior year, partially offset by $315,000 of additional preferred stock dividends associated with issuance of the same preferred shares described in the previous paragraph as well as an increase of approximately $454,000 in additional deemed dividends and approximately $194,000 in accretion of discounts associated with the Series C Preferred shares and warrants issued in connection with the Bird & Cronin Acquisitionin comparison to deemed dividends associated with Series A Preferred in December 2016.

The deemed dividends reflect the difference between the underlying common share value of the issued preferred shares as if converted, based on the closing price of the Company’s common stock on the date of the issuance, less an amount of the purchase price assigned to the preferred shares in an allocation of the purchase price between the preferred shares and the common stock warrants that were issued with the preferred shares.

Liquidity and Capital Resources

We have historically financed operations through cash from operating activities, available cash reserves, borrowings under a line of credit facility (see, Line of Credit, below) and sales of equity securities. We expect to obtain capital for future acquisitions using borrowings and proceeds from debt and equity offerings. Working capital was $9,091,000 as of December 31, 2017, compared to working capital of $5,834,000 as of June 30, 2017. The current ratio was 1.6 to 1 as of December 31, 2017 and 1.8 to 1 as of June 30, 2017.

Cash and Cash Equivalents

Our cash and cash equivalents position increased $3,397,000 to $3,652,000 as of December 31, 2017, compared to $255,000 as of June 30, 2017. The primary source of cash in the six months ended December 31, 2017, was approximately $1,677,000 net cash provided by operating activities, net borrowings of $4,571,000 under our line of credit and net proceeds of approximately $6,600,000 from sale of our Series C Preferred and warrants in connection with the Acquisition of Bird & Cronin.

Accounts Receivable

Trade accounts receivable, net of allowance for doubtful accounts, increased approximately $2,104,000, or 39.8%, to $7,385,000 as of December 31, 2017, from $5,281,000 as of June 30, 2017. The increase was primarily due to the addition of the Bird & Cronin that added $1,819,000 in accounts receivable as of December 31, 2017. We believe that our estimate of the allowance for doubtful accounts is adequate based on our historical experience and relationships with our customers. Accounts receivable are generally collected within approximately 30 days of invoicing.

Inventories

Inventories, net of reserves, increased $4,207,000 or 56.9%, to $11,605,000 as of December 31, 2017, compared to $7,398,000 as of June 30, 2017. The increase was driven by the addition of the Bird & Cronin subsidiary that had $4,707,000 of net inventory as of December 31, 2017. Inventory levels fluctuate based on timing of large inventory purchases from domestic and overseas suppliers as well as variations in sales and production activities. We believe that our allowance for inventory obsolescence is adequate based on our analysis of inventory, sales trends, and historical experience.

Accounts Payable

Accounts payable increased approximately $2,116,000 or 90.6%, to $4,451,000 as of December 31, 2017 from $2,335,000 as of June 30, 2017. The increase was driven primarily by the addition of the Bird & Cronin subsidiary that had $1,346,000 of accounts payable at December 31, 2017. The increase was also attributable to an increase in days payable from approximately 27 to 34.

Line of Credit

Our line of credit balance increased $4,571,000 to $6,743,000 as of December 31, 2017, compared to $2,172,000 as of June 30, 2017. We drew $5,000,000 on September 29, 2017 in anticipation of closing the Acquisition of Bird & Cronin on October 2, 2017.

Debt

Long-term debt, excluding current installments, decreased $75,000 to $387,000 as of December 31, 2017, compared to $462,000 as of June 30, 2017. Our long-term debt is primarily comprised of the mortgage loan on our office and manufacturing facility in Tennessee and also includes loans related to equipment and a vehicle. The principal balance on the mortgage loan was approximately $445,000 of which $310,000 is classified as long-term debt, with monthly principal and interest payments of $13,278 through January 2021.

In conjunction with the sale and leaseback of our corporate headquarters in August 2014, we entered into a 15-year building lease that we treated as a capital lease valued at $3,800,000. We are amortizing the capital lease asset on a straight line basis over 15 years at approximately $21,000 per month, or $63,000 per quarter. Accumulated amortization of the capital lease asset was approximately $861,000 at December 31, 2017. The building sale resulted in a profit of $2,300,000 that is treated as a deferred gain that is amortized as an offset to amortization expense over the life of the lease at $12,500 per month, or approximately $37,500 per quarter. The balance of the deferred gain at December 31, 2017 was approximately $1,755,000. Lease payments, currently approximately $29,000, are payable monthly and increase approximately 2% per year over the life of the lease. The balance of the capital lease liability was approximately $3,186,000 at December 31, 2017. Imputed interest for the quarter ended December 31, 2017, was approximately $45,000.

Deferred Income Tax Assets

A valuation allowance is required when there is significant uncertainty as to the realizability of deferred income tax assets. The ability to realize deferred income tax assets is dependent upon our ability to generate sufficient taxable income within the carryforward periods provided for in the tax law for each tax jurisdiction. We have determined that we do not meet the “more likely than not” threshold that deferred income tax assets will be realized. Accordingly, a valuation allowance is required. Any reversal of the valuation allowance in future periods will favorably impact our results of operations in the period of reversal. As of December 31, 2017 and June 30, 2017, we recorded a full valuation allowance against our net deferred income tax assets. This resulted in no reported income tax expense associated with the operating profit reported during the three and six months ended December 31, 2017.

Inflation

Our revenues and net income have not been unusually affected by inflation or price increases for raw materials and parts from vendors.

Stock Repurchase Plans

We have a stock repurchase plan available to us at the discretion of the Board of Directors. Approximately $449,000 remained of this authorization as of December 31, 2017. No purchases have been made under this plan since September 28, 2011.

Off-Balance Sheet Arrangements

As of December 31, 2017, we had no off-balance sheet arrangements.

Critical Accounting Policies

The preparation of our financial statements requires that we make estimates and judgments. We base these on historical experience and on other assumptions that we believe to be reasonable. Our critical accounting policies are discussed in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended June 30, 2017. There have been no material changes to the critical accounting policies previously disclosed in that report.

I ~~Item~~tem 3. Quantitative and Qualitative Disclosures ~~about~~About Market Risk

There have been no material changes to information from that presented in our Annual Report on Form 10-K for the year ended June 30, ~~2016.~~2017.

~~Item~~

Item 4. Controls and Procedures

Disclosure Controls and Procedures

~~Our~~

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods that are specified in the Securities and Exchange Commission’s (“SEC”) rules and forms and that such information is accumulated and communicated to management, ~~with the participation of~~including our Chief Executive Officer and Chief Financial Officer, ~~has~~as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as ~~such term is~~ defined in ~~Rules~~Rule 13a-15(e) and 15d-15(e) ~~under~~of the ~~Securities~~ Exchange ~~Act of 1934, as amended (the "Exchange Act"))~~Act) as of ~~the end of the period covered by this report.~~December 31, 2017. Based on ~~such~~this evaluation, our Chief Executive Officer and Chief Financial Officer ~~have~~ concluded that ~~as of March 31, 2017,~~ our disclosure controls and procedures were ~~effective.~~effective as of December 31, 2017.

Changes in Internal Control over Financial Reporting

~~There~~

On October 2, 2017 we acquired the assets of Bird & Cronin. We have ~~not been any~~established oversight, procedures, and controls over financial reporting to accurately consolidate the financial statements of Bird & Cronin and to properly reflect acquisition-related accounting and disclosures. We are continuing to evaluate the design of internal controls over financial reporting for the Bird & Cronin subsidiary.

Except as described above, there were no changes in our internal control over financial reporting (as ~~such term is~~ defined in ~~Rules~~Rule 13a-15(f) ~~and 15d-15(f)~~ under the Exchange Act) during the ~~fiscal~~ quarter ended ~~March~~December 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~PART~~PART II. OTHER INFORMATION

I~~Item~~tem 6. Exhibits

(a) Exhibits

~~(a)~~3.1(a)

~~Exhibits~~

Amended and Restated Articles of Incorporation of Dynatronics Corporation, incorporated by reference to Exhibit ~~No.~~	~~Description~~3.1 to Registration Statement on Form S-3 filed January 27, 2017

~~2.1~~3.1(b)	~~Asset Purchase Agreement dated March 21, 2017 (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K, filed March 22, 2017)~~

~~3.1~~	~~Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 of Registration Statement on Form S-3, Reg. No. 333- 215800, filed January 27, 2017)~~

~~3.2~~	Certificate of Designations, Preferences and Rights of ~~the~~ Series B Convertible Preferred Stock of Dynatronics Corporation, ~~(incorporated~~incorporated by reference to ExExhibit 3.1 to Current Report on Form 8-K, filed April 4, ~~2017)~~2017

~~4.2~~3.1(c)	~~Form~~ Certificate of ~~certificate representing~~Designation of Rights and Preferences of Series BC Non-Voting Convertible Preferred Stock ~~(incorporated~~as filed with the Utah Division of Corporations and Commercial Code September 29, 2017, incorporated by reference to ~~Ex 4.2 to Registration Statement on Form S-3 filed April 14, 2017)~~

~~4.3~~	~~Form of Warrant (incorporated by reference~~Exhibit 3.1 to Current Report on Form 8-K filed ~~on March 22, 2017)~~October 6, 2017

~~10.1~~3.1(d)	~~Securities Purchase Agreement dated March 21,~~ Certificate of Designation of Rights and Preferences of Series D Non-Voting Convertible Preferred Stock as filed with the Utah Division of Corporations and Commercial Code September 29, 2017, ~~(incorporated~~incorporated by reference to Exhibit ~~10.3 of~~3.2 to Current Report on Form 8-K filed ~~March 22,~~October 6, 2017

10.1	Asset Purchase Agreement, dated September 26, 2017, by and between Dynatronics Corporation and Bird & Cronin, Inc., incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed September 27, 2017)

10.2	~~Form of Registration Rights~~ Lease Agreement, ~~(incorporated~~dated October 2, 2017, by and between Dynatronics Corporation and Trapp Road Limited Liability Company, incorporated by reference to Exhibit ~~10.3 of~~10.2 to Current Report on Form 8-K filed ~~March 22, 2017)~~October 6, 2017

10.3	~~Loan and Security~~ Securities Purchase Agreement dated ~~March 31,~~September 26, 2017, ~~(incorporated~~by and between Dynatronics Corporation and each of the Investors signatory thereto, incorporated by reference to Exhibit ~~10.1 of~~10.3 to Current Report on Form 8-K filed ~~April 4, 2017)~~September 27, 2017

10.4	Form of Registration Rights Agreement to be entered into by and between Dynatronics Corporation and each Investor signatory thereto, incorporated by reference to Exhibit 10.4 to Current Report on Form 8-K filed September 27, 2017

10.5	Form of Registration Rights Agreement to be entered into by and between Dynatronics Corporation and Bird & Cronin, Inc., incorporated by reference to Exhibit 10.5 to Current Report on Form 8-K filed September 27, 2017

10.6	Modification Agreement, dated October 2, 2017 among Dynatronics Corporation, Hausmann Enterprises, LLC and Bird & Cronin, LLC as Borrowers and Bank of the West, incorporated by reference to Exhibit 10.6 to Current Report on Form 8-K filed October 6, 2017

11	Computation of Net Income per Share (included in Notes to Consolidated Financial Statements)

31.1	Certification under Rule 13a-14(a)/15d-14(a) of principal executive officer ~~(filed herewith)~~

31.2	Certification under Rule 13a-14(a)/15d-14(a) of principal financial officer ~~(filed herewith)~~

3232.1	Certifications under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350) ~~(filed herewith)~~

~~101 INS~~101.INS	XBRL Instance Document*Document

~~101 SCH~~101.CAL	XBRL Taxonomy Extension Schema Document*Document

~~101 CAL~~101.SCH	XBRL Taxonomy Extension Calculation Linkbase Document*Document

~~101 DEF~~101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*Document

~~101 LAB~~101.LAB	XBRL ~~Labels~~Taxonomy Extension Label Linkbase Document*Document

~~101 PRE~~101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document*Document

	DYNATRONICS CORPORATION
	~~Registrant~~
Date: February 13, 2018	By:	/s/ Kelvyn H. Cullimore, Jr.
		Kelvyn H. Cullimore, Jr.
		President and Chief Executive Officer (Principal Executive Officer)



~~Date: May 15, 2017~~	~~/s/ Kelvyn H. Cullimore, Jr.~~
Date: February 13, 2018	~~Kelvyn H. Cullimore, Jr.~~
By:	~~President and Chief Executive Officer~~
	~~(Principal Executive Officer)~~
/s/ David A. Wirthlin

David A. Wirthlin
~~Date: May 15, 2017~~	~~/s/ David A. Wirthlin~~
	~~David A. Wirthlin~~
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

	Three Months Ended				Nine Months Ended
	March 31,				March 31,
	2017		2016		2017		2016
Basic weighted-average number of common shares outstanding during the period		3,022,443		2,731,282		2,914,229		2,681,493
Weighted-average number of dilutive potential common stock outstanding during the period		-		-		-		-
Diluted weighted-average number of common and potential common shares outstanding during the period		3,022,443		2,731,282		2,914,229		2,681,493

	Number of Options			Weighted- Average Exercise Price
Outstanding at beginning of period		121,557		$	3.57
Granted		49,500			2.83
Exercised		-			-
Cancelled		(2,639	)		4.63
Outstanding at end of period		168,418			3.33

Exercisable at end of period		75,901		$	4.47

	March 31, 2017			June 30, 2016
Raw materials	$	2,274,898		$	2,059,048
Finished goods		3,931,215		$	3,353,964
Inventory obsolescence reserve		(422,786	)		(415,758	)
	$	5,783,327			4,997,254